The healthcare artificial intelligence company known as Tempus has announced that it has made a major acquisition. Tempus and its founder Eric Lefkofsky have finalized a deal where it will purchase Akesogen which is a commercial laboratory that provides genomics and other medicine services. Tempus revealed that this acquisition will strengthen its expansion into diseases outside of cancer. It will also allow the company to provide strategic capabilities that will compliment its current operations. The financial terms of the acquisition were not disclosed as of right now. According to Tempus, Aksegogen is CLIA compliant and CAP-accredited. As a result, it is one of the more reputable clinical laboratories in the nation. Akesogen provides a wide range of testing services for things that include microbiome profiling, genome genotyping, epigenomic methylation profiling and risk of cancer.
The founder and chief executive officer of Tempus Eric Lefkofsky made a statement about the recent transaction. He said that acquiring the firm will provide a breadth of capabilities that will become a strategic compliment to Tempus. By acquiring Akesogen, Tempus looks forward to introducing artificial intelligence and data to the healthcare industry. Today, Tempus has an extensive library of both clinical and molecular data along with an operating system that makes the data very practical and useful. Many physicians are able to make decisions based on data which are used to help make discoveries, develop treatments and organize therapies for a variety of different patients. The acquisition of the laboratory Akesogen will help Tempus provide even more beneficial assistance to the medical community.
Learn More : https://interview.net/eric-lefkofsky/